vs
BIOMERICA INC（BMRA）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
Alpha Teknova, Inc.的季度营收约是BIOMERICA INC的8.3倍（$10.0M vs $1.2M）。Alpha Teknova, Inc.净利率更高（-47.7% vs -109.1%，领先61.4%）。Alpha Teknova, Inc.同比增速更快（7.8% vs -26.0%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs 3.7%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
BMRA vs TKNO — 直观对比
营收规模更大
TKNO
是对方的8.3倍
$1.2M
营收增速更快
TKNO
高出33.8%
-26.0%
净利率更高
TKNO
高出61.4%
-109.1%
两年增速更快
BMRA
近两年复合增速
3.7%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $10.0M |
| 净利润 | $-1.3M | $-4.8M |
| 毛利率 | 4.2% | 32.5% |
| 营业利润率 | -113.5% | -46.2% |
| 净利率 | -109.1% | -47.7% |
| 营收同比 | -26.0% | 7.8% |
| 净利润同比 | -38.9% | 16.8% |
| 每股收益（稀释后） | $-0.45 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRATKNO
| Q4 25 | $1.2M | $10.0M | ||
| Q3 25 | $1.4M | $10.5M | ||
| Q2 25 | $749.0K | $10.3M | ||
| Q1 25 | $1.1M | $9.8M | ||
| Q4 24 | $1.6M | $9.3M | ||
| Q3 24 | $1.8M | $9.6M | ||
| Q2 24 | $1.1M | $9.6M | ||
| Q1 24 | $1.0M | $9.3M |
净利润BMRATKNO
| Q4 25 | $-1.3M | $-4.8M | ||
| Q3 25 | $2.0K | $-4.3M | ||
| Q2 25 | $-1.5M | $-3.6M | ||
| Q1 25 | $-1.2M | $-4.6M | ||
| Q4 24 | $-950.0K | $-5.7M | ||
| Q3 24 | $-1.3M | $-7.6M | ||
| Q2 24 | $-1.4M | $-5.4M | ||
| Q1 24 | $-1.9M | $-8.1M |
毛利率BMRATKNO
| Q4 25 | 4.2% | 32.5% | ||
| Q3 25 | 30.7% | 30.7% | ||
| Q2 25 | -33.0% | 38.7% | ||
| Q1 25 | 1.7% | 30.7% | ||
| Q4 24 | 26.7% | 23.0% | ||
| Q3 24 | 16.0% | 0.9% | ||
| Q2 24 | 2.1% | 29.2% | ||
| Q1 24 | -14.7% | 23.8% |
营业利润率BMRATKNO
| Q4 25 | -113.5% | -46.2% | ||
| Q3 25 | -81.0% | -38.4% | ||
| Q2 25 | -209.1% | -32.9% | ||
| Q1 25 | -108.1% | -50.7% | ||
| Q4 24 | -60.7% | -60.7% | ||
| Q3 24 | -75.7% | -77.6% | ||
| Q2 24 | -136.6% | -53.0% | ||
| Q1 24 | -196.7% | -86.0% |
净利率BMRATKNO
| Q4 25 | -109.1% | -47.7% | ||
| Q3 25 | 0.1% | -41.0% | ||
| Q2 25 | -206.1% | -34.7% | ||
| Q1 25 | -103.9% | -47.4% | ||
| Q4 24 | -58.1% | -61.7% | ||
| Q3 24 | -72.8% | -79.0% | ||
| Q2 24 | -127.1% | -55.8% | ||
| Q1 24 | -188.6% | -87.2% |
每股收益（稀释后）BMRATKNO
| Q4 25 | $-0.45 | $-0.08 | ||
| Q3 25 | $0.00 | $-0.08 | ||
| Q2 25 | $-0.99 | $-0.07 | ||
| Q1 25 | $-0.48 | $-0.09 | ||
| Q4 24 | $-0.06 | $-0.09 | ||
| Q3 24 | $-0.63 | $-0.15 | ||
| Q2 24 | $-2.57 | $-0.13 | ||
| Q1 24 | $-0.11 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $21.3M |
| 总债务越低越好 | — | $13.1M |
| 股东权益账面价值 | $4.4M | $68.8M |
| 总资产 | $6.0M | $103.6M |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资BMRATKNO
| Q4 25 | $2.5M | $21.3M | ||
| Q3 25 | $3.1M | $22.1M | ||
| Q2 25 | $3.1M | $24.0M | ||
| Q1 25 | $3.1M | $26.3M | ||
| Q4 24 | $2.4M | $30.4M | ||
| Q3 24 | $2.8M | $31.7M | ||
| Q2 24 | $4.2M | $18.6M | ||
| Q1 24 | $5.3M | $21.6M |
总债务BMRATKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
股东权益BMRATKNO
| Q4 25 | $4.4M | $68.8M | ||
| Q3 25 | $5.2M | $72.7M | ||
| Q2 25 | $4.1M | $76.1M | ||
| Q1 25 | $5.5M | $78.6M | ||
| Q4 24 | $5.1M | $82.4M | ||
| Q3 24 | $5.3M | $87.3M | ||
| Q2 24 | $6.6M | $78.9M | ||
| Q1 24 | $7.8M | $83.4M |
总资产BMRATKNO
| Q4 25 | $6.0M | $103.6M | ||
| Q3 25 | $6.9M | $107.6M | ||
| Q2 25 | $5.9M | $110.5M | ||
| Q1 25 | $7.4M | $114.0M | ||
| Q4 24 | $7.3M | $118.8M | ||
| Q3 24 | $7.9M | $124.1M | ||
| Q2 24 | $9.3M | $115.4M | ||
| Q1 24 | $10.3M | $120.8M |
负债/权益比BMRATKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-810.0K |
| 自由现金流率自由现金流/营收 | — | -8.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-9.8M |
8季度趋势，按日历期对齐
经营现金流BMRATKNO
| Q4 25 | $-991.0K | $-462.0K | ||
| Q3 25 | $-268.0K | $-2.0M | ||
| Q2 25 | $-661.0K | $-2.1M | ||
| Q1 25 | $-1.0M | $-4.1M | ||
| Q4 24 | $-791.0K | $-936.0K | ||
| Q3 24 | $-1.3M | $-2.1M | ||
| Q2 24 | $-1.0M | $-2.8M | ||
| Q1 24 | $-1.8M | $-6.6M |
自由现金流BMRATKNO
| Q4 25 | — | $-810.0K | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-4.3M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-1.1M | $-3.0M | ||
| Q1 24 | — | $-6.7M |
自由现金流率BMRATKNO
| Q4 25 | — | -8.1% | ||
| Q3 25 | — | -22.6% | ||
| Q2 25 | — | -22.4% | ||
| Q1 25 | — | -44.0% | ||
| Q4 24 | — | -16.2% | ||
| Q3 24 | — | -25.0% | ||
| Q2 24 | -95.5% | -30.7% | ||
| Q1 24 | — | -71.8% |
资本支出强度BMRATKNO
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 3.5% | ||
| Q2 24 | 2.1% | 1.2% | ||
| Q1 24 | 0.0% | 1.2% |
现金转化率BMRATKNO
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRA
暂无分部数据
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
